MCID: RTN020
MIFTS: 46

Retinal Vascular Disease

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Vascular Disease

MalaCards integrated aliases for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 15
Retinal Vascular 54 71
Retina Circulation Disorder 12
Retinal Vascular Disorder 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 49 C35170
SNOMED-CT 67 57534004
UMLS 71 C0154833 C0549652

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to vascular disease and retinal vein occlusion, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Folate Metabolism and MicroRNAs in cancer. The drugs Ketorolac and Zinc have been mentioned in the context of this disorder. Affiliated tissues include endothelial, retina and eye, and related phenotypes are liver/biliary system and vision/eye

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 533, show less)
# Related Disease Score Top Affiliating Genes
1 vascular disease 31.9 VEGFA PLG MTHFR MIR21 MIR126 KDR
2 retinal vein occlusion 31.8 VEGFA SERPINF1 MTHFR KDR
3 central retinal vein occlusion 31.3 VEGFA SERPINF1 PLG MTHFR
4 intraocular pressure quantitative trait locus 31.3 VEGFA SERPINF1 CRYAA CCN2
5 branch retinal artery occlusion 31.3 VEGFA PLG MTHFR CRYAA
6 microvascular complications of diabetes 1 31.2 VEGFA SERPINF1 INS CCN2 AKR1B1
7 macular retinal edema 31.2 VEGFA SERPINF1 KDR INS CRYAA ALB
8 retinal artery occlusion 31.2 VEGFA PLG MTHFR KDR CRYAA
9 kuhnt-junius degeneration 31.2 VEGFA PLG MIR126 KDR CRYAA
10 macular degeneration, age-related, 1 31.2 VEGFA SERPINF1 PLG KDR INS H2AC18
11 atherosclerosis susceptibility 31.1 VEGFA MTHFR INS ALB
12 retinal disease 31.1 NDP H2AC18 CRYAA ALB AIPL1
13 diabetic macular edema 31.1 VEGFA SERPINF1 AKR1B1
14 lipid metabolism disorder 31.1 MIR21 MIR126 INS H2AC18
15 exudative vitreoretinopathy 1 31.0 VEGFA SERPINF1 NDP KDR CRYAA
16 hyperglycemia 31.0 MIR126 INS ALB AKR1B1
17 coats disease 31.0 VEGFA NDP KDR
18 background diabetic retinopathy 30.9 VEGFA KDR INS ALB AKR1B1
19 endophthalmitis 30.9 VEGFA PLG CRYAA ALB
20 retinal vascular occlusion 30.9 VEGFA SERPINF1 PLG MTHFR KDR CRYAA
21 diabetes mellitus 30.9 VEGFA MTHFR MIR20A MIR126 KDR INS
22 neovascular glaucoma 30.9 VEGFA PLG KDR CRYAA
23 corneal neovascularization 30.8 VEGFA SERPINF1 PLG KDR CRYAA
24 retinal detachment 30.8 VEGFA SERPINF1 NDP CCN2
25 rubeosis iridis 30.8 VEGFA PLG
26 macular holes 30.7 VEGFA SERPINF1 PLG CRYAA
27 pre-eclampsia 30.7 VEGFA MTHFR MIR126 KDR INS ALB
28 diabetic neuropathy 30.7 VEGFA INS AKR1B1
29 retinal microaneurysm 30.7 VEGFA MIR20A INS AKR1B1
30 muscular dystrophy 30.7 VEGFA LIF KDR INS CCN2 ALB
31 central retinal artery occlusion 30.7 VEGFA PLG MTHFR CRYAA
32 leukostasis 30.7 VEGFA SERPINF1 KDR
33 cataract 30.6 VEGFA SERPINF1 MTHFR INS CRYAA ALB
34 polyneuropathy 30.6 VEGFA INS ALB AKR1B1
35 microvascular complications of diabetes 5 30.6 VEGFA SERPINF1 PLG MIR30A MIR21 MIR20B
36 telangiectasis 30.6 VEGFA NDP H2AC18
37 impotence 30.6 VEGFA INS ALB
38 fundus dystrophy 30.6 VEGFA SERPINF1 KDR INS CRYAA ALB
39 non-alcoholic fatty liver disease 30.6 MIR30A MIR21 MIR126 INS ALB
40 macular dystrophy, dominant cystoid 30.6 VEGFA SERPINF1 CRYAA
41 retinitis pigmentosa 30.5 VEGFA SERPINF1 LIF INS H2AC18 CRYAA
42 hypertension, essential 30.5 VEGFA PLG MTHFR MIR30A MIR21 MIR126
43 eclampsia 30.5 VEGFA MTHFR ALB
44 lipoprotein quantitative trait locus 30.5 VEGFA PLG MIR21 MIR126 KDR ALB
45 chronic kidney disease 30.5 VEGFA MTHFR INS CCN2 ALB
46 placenta disease 30.5 VEGFA MTHFR INS H2AC18
47 vitreoretinopathy, neovascular inflammatory 30.5 VEGFA CRYAA CCN2
48 apnea, obstructive sleep 30.5 VEGFA INS ALB
49 atrial fibrillation 30.4 MIR21 MIR126 INS ALB
50 migraine with or without aura 1 30.4 PLG MTHFR INS H2AC18 ALB
51 heart disease 30.4 VEGFA MTHFR MIR21 MIR126 KDR INS
52 sleep apnea 30.3 VEGFA INS ALB
53 deficiency anemia 30.3 LIF INS H2AC18 ALB
54 leber plus disease 30.3 SERPINF1 INS CRYAA ALB AIPL1
55 pulmonary hypertension 30.2 VEGFA PLG MIR21 MIR20A KDR ALB
56 intestinal disease 30.2 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
57 disease of mental health 30.2 MIR30A MIR21 MIR126 INS H2AC18 ALB
58 arteries, anomalies of 30.2 VEGFA PLG MIR30A MIR21 MIR146B MIR126
59 peripheral nervous system disease 30.1 VEGFA MIR21 MIR126 INS H2AC18 CRYAA
60 hyperuricemia 30.1 MTHFR INS ALB
61 eye disease 30.0 VEGFA SERPINF1 MIR30A MIR21 MIR20B MIR20A
62 lung cancer susceptibility 3 30.0 VEGFA MIR30A MIR21 MIR20B MIR146B MIR126
63 genetic central nervous system and retinal vascular disease 12.3
64 rare central nervous system and retinal vascular disease 12.3
65 retinal degeneration 11.6
66 exudative vitreoretinopathy 11.5
67 retinitis pigmentosa 10 11.1
68 leukoencephalopathy, brain calcifications, and cysts 11.1
69 hemifacial spasm 10.7 VEGFA MTHFR
70 retinal perforation 10.7 VEGFA PLG CRYAA
71 eales disease 10.7
72 venous insufficiency 10.7 VEGFA NDP MTHFR
73 diabetic polyneuropathy 10.7 VEGFA INS AKR1B1
74 capillary disease 10.7 VEGFA KDR ALB
75 autoimmune disease of cardiovascular system 10.7 PLG MTHFR H2AC18
76 kidney hypertrophy 10.7 INS CCN2 ALB
77 thrombophlebitis 10.7 PLG MTHFR ALB
78 decubitus ulcer 10.7 VEGFA INS ALB
79 nephrosclerosis 10.7 VEGFA MTHFR INS CCN2
80 polymyositis 10.7 MIR30A MIR21 MIR146B
81 severe nonproliferative diabetic retinopathy 10.7 VEGFA INS ALB AKR1B1
82 blood group, globoside system 10.7 VEGFA PLG CRYAA ALB
83 intussusception 10.7 VEGFA MIR126 KDR ALB
84 inherited blood coagulation disease 10.7 PLG MTHFR ALB
85 moyamoya disease 1 10.7 VEGFA PLG MTHFR
86 vascular cancer 10.7 VEGFA PLG KDR
87 chronic ulcer of skin 10.7 VEGFA INS ALB
88 intermediate coronary syndrome 10.7 PLG MIR126 INS
89 persistent fetal circulation syndrome 10.7 VEGFA INS ALB
90 hepatic vascular disease 10.7 VEGFA PLG ALB
91 senile cataract 10.7 SERPINF1 CRYAA ALB
92 drug-induced lupus erythematosus 10.7 KDR H2AC18 ALB
93 necrotizing fasciitis 10.7 PLG H2AC18 ALB
94 colorectal adenoma 10.7 VEGFA MTHFR MIR21 INS
95 retroperitoneal hemangiopericytoma 10.7 VEGFA INS
96 vitreous disease 10.7 VEGFA PLG NDP CRYAA CCN2
97 diabetic cataract 10.7 VEGFA SERPINF1 INS CRYAA AKR1B1
98 arteriovenous malformations of the brain 10.7 VEGFA PLG KDR
99 miyoshi muscular dystrophy 1 10.7 MIR30A MIR21 MIR146B
100 ovarian hyperstimulation syndrome 10.7 VEGFA KDR INS ALB
101 actinomycosis 10.7 INS H2AC18 ALB
102 exanthem 10.7 VEGFA KDR H2AC18 ALB
103 lymphangioma 10.7 VEGFA MIR20A KDR H2AC18
104 autonomic nervous system disease 10.6 MIR126 INS ALB AKR1B1
105 amino acid metabolic disorder 10.6 MTHFR H2AC18 CRYAA ALB
106 osteonecrosis 10.6 VEGFA PLG MTHFR
107 degeneration of macula and posterior pole 10.6 VEGFA SERPINF1 KDR H2AC18 CRYAA
108 breast carcinoma in situ 10.6 VEGFA MIR30A KDR H2AC18
109 alport syndrome 10.6 VEGFA MIR21 CRYAA ALB
110 breast angiosarcoma 10.6 VEGFA KDR
111 limb ischemia 10.6 VEGFA MIR21 KDR
112 cardiovascular organ benign neoplasm 10.6 VEGFA KDR H2AC18
113 pulmonary artery disease 10.6 VEGFA PLG MTHFR MIR126 ALB
114 intestinal benign neoplasm 10.6 VEGFA MIR21 MIR20A H2AC18
115 carpal tunnel syndrome 10.6 VEGFA INS CCN2
116 x-linked recessive disease 10.6 NDP H2AC18 CRYAA ALB
117 hair disease 10.6 VEGFA INS H2AC18 ALB
118 sexual disorder 10.6 INS H2AC18 ALB
119 varicose veins 10.6 VEGFA MTHFR KDR
120 prediabetes syndrome 10.6 MIR126 INS ALB
121 livedoid vasculitis 10.6 PLG MTHFR
122 gliosarcoma 10.6 VEGFA KDR H2AC18 ALB
123 glomerular disease 10.6 MIR30A ALB
124 blood protein disease 10.6 VEGFA MTHFR MIR126 H2AC18 ALB
125 x-linked monogenic disease 10.6 NDP H2AC18 CRYAA ALB
126 chromosomal disease 10.6 MIR21 MIR126 H2AC18 CRYAA
127 muscle tissue disease 10.6 MIR126 INS H2AC18 CRYAA
128 blood coagulation disease 10.6 VEGFA PLG MTHFR H2AC18 ALB
129 ovary epithelial cancer 10.6 VEGFA MIR30A MIR21 H2AC18
130 uveal disease 10.6 VEGFA H2AC18 CRYAA
131 malignant ovarian surface epithelial-stromal neoplasm 10.6 VEGFA MIR30A MIR21 H2AC18
132 thyroid gland anaplastic carcinoma 10.6 VEGFA MIR30A MIR146B CRYAA
133 metal metabolism disorder 10.6 INS H2AC18 ALB
134 autoimmune disease of central nervous system 10.6 MIR126 H2AC18 CRYAA ALB
135 heart valve disease 10.6 MIR21 MIR126 H2AC18 ALB
136 corneal disease 10.6 VEGFA H2AC18 CRYAA ALB AKR1B1
137 bronchial disease 10.6 MIR21 MIR126 H2AC18 ALB
138 mineral metabolism disease 10.6 INS H2AC18 ALB
139 acute cystitis 10.6 INS H2AC18 ALB
140 non-alcoholic steatohepatitis 10.6 MIR21 INS CCN2 ALB
141 autoimmune disease of gastrointestinal tract 10.6 INS H2AC18 ALB
142 portal hypertension 10.6 VEGFA KDR INS CCN2 ALB
143 parasitic helminthiasis infectious disease 10.6 MIR21 H2AC18 ALB
144 microvascular complications of diabetes 3 10.6 MIR21 INS CCN2 ALB AKR1B1
145 stomach disease 10.6 MIR20A INS H2AC18 ALB
146 pleural disease 10.6 VEGFA H2AC18 ALB
147 lipid storage disease 10.6 MIR21 INS H2AC18 ALB
148 thyroid gland disease 10.6 MIR146B INS H2AC18 ALB
149 ocular cancer 10.6 PLG MIR30A H2AC18 CRYAA
150 peripheral vascular disease 10.6 VEGFA MTHFR INS H2AC18 ALB
151 oral cavity cancer 10.6 VEGFA MIR30A MIR21 H2AC18
152 autoimmune disease of musculoskeletal system 10.6 MIR30A MIR21 H2AC18 ALB
153 specific developmental disorder 10.6 INS H2AC18 CRYAA ALB
154 suppression of tumorigenicity 12 10.6 VEGFA KDR H2AC18 ALB
155 pharynx cancer 10.6 MIR30A MIR21 MIR126 H2AC18
156 dermatomyositis 10.6 MIR30A MIR21 MIR146B
157 radiation proctitis 10.6 VEGFA KDR
158 bile duct disease 10.6 MIR30A MIR20B H2AC18 ALB
159 melanoma, uveal 10.6 VEGFA PLG H2AC18 CRYAA
160 biliary tract disease 10.6 MIR30A MIR20B H2AC18 ALB
161 carbohydrate metabolic disorder 10.6 INS H2AC18 CRYAA
162 vein disease 10.6 VEGFA PLG MTHFR KDR INS ALB
163 endometriosis 10.6 VEGFA MIR20A MIR126 LIF KDR
164 bile duct cancer 10.6 VEGFA MIR21 KDR H2AC18 ALB
165 central nervous system cancer 10.6 VEGFA MIR30A MIR21 MIR126 H2AC18
166 peptic ulcer disease 10.6 INS H2AC18 ALB
167 pituitary gland disease 10.6 MIR21 INS H2AC18
168 connective tissue cancer 10.6 VEGFA MIR30A MIR21 MIR126 H2AC18
169 intracranial sinus thrombosis 10.6 PLG MTHFR
170 muscular disease 10.6 MIR126 INS H2AC18 CRYAA ALB
171 ovary adenocarcinoma 10.6 VEGFA MIR30A H2AC18
172 eye degenerative disease 10.6 VEGFA KDR H2AC18 CRYAA ALB AIPL1
173 mature b-cell neoplasm 10.6 MIR20B MIR126 H2AC18
174 lens disease 10.6 VEGFA INS H2AC18 CRYAA ALB AKR1B1
175 systemic scleroderma 10.6 MIR30A MIR21 INS H2AC18 CCN2
176 bile duct adenocarcinoma 10.6 MIR30A MIR21 MIR20B H2AC18 ALB
177 gastrointestinal system benign neoplasm 10.6 MIR30A MIR21 MIR20A INS H2AC18
178 nutritional deficiency disease 10.6 MTHFR H2AC18 ALB
179 lysosomal storage disease 10.6 MIR21 INS H2AC18 ALB
180 cervix disease 10.6 MIR30A MIR21 MIR146B MIR126 H2AC18
181 endocrine organ benign neoplasm 10.6 MIR21 MIR126 H2AC18
182 esophageal disease 10.6 MIR30A MIR21 MIR126 H2AC18 ALB
183 bladder disease 10.6 MIR30A MIR21 MIR146B MIR126 H2AC18
184 constipation 10.5 INS H2AC18 ALB AKR1B1
185 clear cell renal cell carcinoma 10.5 VEGFA MIR30A MIR21 MIR126 KDR
186 pulmonary fibrosis, idiopathic 10.5 VEGFA MIR30A MIR21 CCN2 ALB
187 cell type benign neoplasm 10.5 VEGFA MIR30A MIR21 MIR126 INS H2AC18
188 heart conduction disease 10.5 PLG MIR21 MIR126 INS H2AC18 ALB
189 acroosteolysis 10.5 VEGFA ALB
190 leukocyte disease 10.5 VEGFA MIR30A MIR21 MIR126 H2AC18 ALB
191 autonomic nervous system neoplasm 10.5 VEGFA MIR30A MIR21 MIR20A MIR126 H2AC18
192 bone marrow cancer 10.5 VEGFA MIR30A MIR21 MIR126 H2AC18 ALB
193 peripheral nervous system neoplasm 10.5 VEGFA MIR30A MIR21 MIR20A MIR126 H2AC18
194 bone inflammation disease 10.5 VEGFA MIR30A MIR21 MIR126 H2AC18 ALB
195 critical illness polyneuropathy 10.5 INS ALB
196 diabetes mellitus, type i 10.5 VEGFA MIR21 INS H2AC18 ALB AKR1B1
197 cerebral degeneration 10.5 H2AC18 CRYAA ALB
198 laryngeal disease 10.5 MIR21 MIR20A H2AC18
199 breast disease 10.5 VEGFA MIR30A MIR21 MIR20A MIR126 H2AC18
200 autonomic neuropathy 10.5 INS ALB AKR1B1
201 pulmonary disease, chronic obstructive 10.5 MIR21 MIR126 INS H2AC18 CCN2 ALB
202 ovarian disease 10.5 VEGFA MIR30A MIR21 MIR126 INS ALB
203 uterine anomalies 10.5 MIR30A MIR21 MIR20B MIR146B MIR126 H2AC18
204 pancreatic adenocarcinoma 10.5 VEGFA MIR21 KDR INS CCN2 ALB
205 overnutrition 10.5 MIR30A MIR21 MIR126 INS H2AC18 ALB
206 bone resorption disease 10.5 INS H2AC18 ALB
207 parasitic protozoa infectious disease 10.5 KDR H2AC18 ALB
208 lymphatic system cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
209 lymphatic system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
210 colonic disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
211 upper respiratory tract disease 10.5 MIR30A MIR21 MIR20A MIR126 H2AC18 ALB
212 male reproductive organ cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
213 prostate disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
214 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.5 VEGFA MIR21 MIR126 INS H2AC18 CRYAA
215 male reproductive system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
216 reproductive system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
217 autosomal genetic disease 10.5 VEGFA MIR21 MIR126 INS H2AC18 CRYAA
218 large intestine cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
219 respiratory system cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
220 female reproductive system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
221 thoracic cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
222 respiratory system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
223 gastrointestinal system cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
224 gastrointestinal system disease 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 H2AC18
225 squamous cell carcinoma, head and neck 10.5 VEGFA MIR30A MIR21 MIR146B KDR H2AC18
226 integumentary system disease 10.5 VEGFA MIR30A MIR21 MIR126 INS H2AC18
227 osteoporosis 10.5 VEGFA NDP MTHFR MIR21 LIF INS
228 myeloma, multiple 10.5 VEGFA MIR30A MIR21 MIR126 KDR H2AC18
229 leukemia, chronic lymphocytic 10.5 VEGFA MIR30A MIR21 MIR20A MIR126 H2AC18
230 endocrine gland cancer 10.5 MIR30A MIR21 MIR20A MIR146B MIR126 KDR
231 urinary system disease 10.4 MIR30A MIR21 MIR20B MIR126 INS H2AC18
232 central nervous system disease 10.4 MIR30A MIR21 MIR146B MIR126 H2AC18 CRYAA
233 immune system disease 10.4 MIR30A MIR21 MIR20B MIR20A MIR146B MIR126
234 leukemia, acute myeloid 10.4 VEGFA MIR30A MIR21 MIR126 KDR H2AC18
235 pancreas disease 10.4 MIR30A MIR21 MIR146B MIR126 INS H2AC18
236 blood platelet disease 10.4 VEGFA H2AC18 ALB
237 endocrine system disease 10.4 MIR30A MIR21 MIR146B MIR126 INS H2AC18
238 lymphoma, non-hodgkin, familial 10.4 VEGFA MIR30A MIR21 MIR20A MIR146B MIR126
239 renal cell carcinoma, nonpapillary 10.4 VEGFA MIR30A MIR21 MIR126 KDR H2AC18
240 bone remodeling disease 10.4 INS H2AC18 ALB
241 inherited metabolic disorder 10.4 MTHFR MIR30A MIR21 MIR126 INS H2AC18
242 cardiovascular system disease 10.4 PLG MTHFR MIR30A MIR21 MIR126 INS
243 esophageal cancer 10.4 VEGFA MTHFR MIR30A MIR21 MIR126 KDR
244 hematologic cancer 10.4 VEGFA MIR30A MIR21 MIR20A MIR146B MIR126
245 tongue disease 10.4 VEGFA MIR30A MIR21
246 connective tissue disease 10.4 VEGFA MIR30A MIR21 MIR146B MIR126 H2AC18
247 cervical cancer 10.4 VEGFA MTHFR MIR30A MIR21 MIR20A MIR146B
248 intrinsic cardiomyopathy 10.4 MIR21 MIR126 H2AC18
249 kidney cancer 10.4 VEGFA MIR21 MIR20B MIR20A MIR126 KDR
250 cerebroretinal microangiopathy with calcifications and cysts 1 10.3
251 transient retinal arterial occlusion 10.3
252 irvan syndrome 10.3
253 nervous system disease 10.3 VEGFA MIR30A MIR21 MIR20A MIR146B MIR126
254 body mass index quantitative trait locus 11 10.3 VEGFA MIR30A MIR21 MIR126 LIF INS
255 myocardial infarction 10.3 VEGFA PLG MTHFR MIR30A MIR21 MIR126
256 glucose metabolism disease 10.3 VEGFA MIR30A MIR21 MIR20A MIR146B MIR126
257 acquired metabolic disease 10.3 VEGFA MIR30A MIR21 MIR20A MIR146B MIR126
258 neuroretinitis 10.3
259 retinitis 10.3
260 motor neuron disease 10.2 VEGFA LIF INS H2AC18
261 yemenite deaf-blind hypopigmentation syndrome 10.2
262 joint laxity, short stature, and myopia 10.2
263 myopia 10.2
264 pancreatic cancer 10.2 VEGFA PLG MIR30A MIR21 MIR20A MIR126
265 thrombophilia 10.2
266 microvascular complications of diabetes 2 10.2
267 open-angle glaucoma 10.1
268 diabetes mellitus, noninsulin-dependent 10.1 VEGFA PLG MTHFR MIR30A MIR21 MIR146B
269 ovarian cancer 10.1 VEGFA PLG MIR30A MIR21 MIR146B MIR126
270 glaucoma, primary open angle 10.1
271 strabismus 10.1
272 coronary heart disease 1 10.1
273 antiphospholipid syndrome 10.1
274 mechanical strabismus 10.1
275 body mass index quantitative trait locus 1 10.1
276 hypoxia 10.1
277 primary bacterial infectious disease 10.0 MIR21 H2AC18 ALB
278 suppression amblyopia 10.0
279 amblyopia 10.0
280 posterior uveitis 10.0
281 hemangioma 10.0
282 neuropathy 10.0
283 vitreoretinopathy 10.0
284 sarcoidosis 1 10.0
285 schizophrenia 10.0
286 major affective disorder 8 10.0
287 major affective disorder 9 10.0
288 cytomegalovirus retinitis 10.0
289 arteriosclerosis 10.0
290 bipolar disorder 10.0
291 neurofibromatosis 10.0
292 ocular hypertension 10.0
293 ndp-related retinopathies 10.0
294 weber syndrome 10.0
295 breast cancer 10.0 VEGFA PLG MTHFR MIR30A MIR21 MIR20A
296 facioscapulohumeral muscular dystrophy 1 10.0
297 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
298 hypertensive retinopathy 10.0
299 retinal ischemia 10.0
300 sturge-weber syndrome 9.9
301 thrombophilia due to thrombin defect 9.9
302 3-methylglutaconic aciduria, type iii 9.9
303 alzheimer disease 9.9
304 multiple sclerosis 9.9
305 hypercholesterolemia, familial, 1 9.9
306 thrombophilia due to activated protein c resistance 9.9
307 arterial tortuosity syndrome 9.9
308 immune deficiency disease 9.9
309 nonarteritic anterior ischemic optic neuropathy 9.9
310 asplenia, isolated congenital 9.9
311 autoimmune uveitis 9.9
312 thrombosis 9.9
313 malignant hypertension 9.9
314 dementia 9.9
315 ventricular septal defect 9.9
316 heart septal defect 9.9
317 neuritis 9.9
318 protein s deficiency 9.9
319 liver disease 9.9
320 cavernous hemangioma 9.9
321 acquired immunodeficiency syndrome 9.9
322 fatty liver disease 9.9
323 toxoplasmosis 9.9
324 bronchopulmonary dysplasia 9.9
325 macular telangiectasia type 2 9.9
326 ocular toxoplasmosis 9.9
327 inherited retinal disorder 9.9
328 systemic lupus erythematosus 9.9
329 retinal vasculitis 9.9
330 myopathy 9.9
331 vasculitis 9.9
332 lupus erythematosus 9.9
333 autoimmune disease 9.8
334 behcet syndrome 9.8
335 coloboma of macula 9.8
336 gaucher disease, type i 9.8
337 laron syndrome 9.8
338 insulin-like growth factor i 9.8
339 norrie disease 9.8
340 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.8
341 birdshot chorioretinopathy 9.8
342 hyperlipoproteinemia, type iii 9.8
343 peripheral artery disease 9.8
344 migraine with aura 9.8
345 glucose intolerance 9.8
346 optic neuritis 9.8
347 migraine without aura 9.8
348 carotid stenosis 9.8
349 gout 9.8
350 primary angle-closure glaucoma 9.8
351 gaucher's disease 9.8
352 capillary hemangioma 9.8
353 chickenpox 9.8
354 posttransplant acute limbic encephalitis 9.8
355 prostate cancer 9.8 VEGFA PLG MIR30A MIR21 MIR20A MIR126
356 triiodothyronine receptor auxiliary protein 9.7
357 von hippel-lindau syndrome 9.7
358 persistent hyperplastic primary vitreous, autosomal recessive 9.7
359 incontinentia pigmenti 9.7
360 aging 9.7
361 branchiootic syndrome 1 9.7
362 homocysteinemia 9.7
363 pars planitis 9.7
364 hemophagocytic lymphohistiocytosis 9.7
365 inflammatory bowel disease 9.7
366 colitis 9.7
367 sensorineural hearing loss 9.7
368 endocarditis 9.7
369 uveitis 9.7
370 papilledema 9.7
371 optic nerve disease 9.7
372 enthesopathy 9.7
373 transient cerebral ischemia 9.7
374 ischemia 9.7
375 carotid artery disease 9.7
376 cerebrovascular disease 9.7
377 carotid artery occlusion 9.7
378 ulcerative colitis 9.7
379 crohn's disease 9.7
380 chorioretinitis 9.7
381 refractive error 9.7
382 48,xyyy 9.7
383 amaurosis fugax 9.7
384 central serous chorioretinopathy 9.7
385 cytokine deficiency 9.7
386 angiomatosis 9.7
387 cerebral amyloid angiopathy, cst3-related 9.6
388 aniridia 1 9.6
389 coarctation of aorta 9.6
390 cone-rod dystrophy 2 9.6
391 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 9.6
392 hemifacial hyperplasia 9.6
393 fibromuscular dysplasia 9.6
394 klippel-trenaunay-weber syndrome 9.6
395 meniere disease 9.6
396 optic nerve hypoplasia, bilateral 9.6
397 pheochromocytoma 9.6
398 exfoliation syndrome 9.6
399 retinoblastoma 9.6
400 digeorge syndrome 9.6
401 wilms tumor 1 9.6
402 anencephaly 9.6
403 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.6
404 galactosemia i 9.6
405 osteoporosis-pseudoglioma syndrome 9.6
406 pseudoxanthoma elasticum 9.6
407 fabry disease 9.6
408 stroke, ischemic 9.6
409 orthostatic intolerance 9.6
410 meningioma, radiation-induced 9.6
411 phace association 9.6
412 meningioma, familial 9.6
413 diabetes mellitus, ketosis-prone 9.6
414 factor xi deficiency 9.6
415 antithrombin iii deficiency 9.6
416 fatty liver disease, nonalcoholic 1 9.6
417 cyanosis, transient neonatal 9.6
418 ras-associated autoimmune leukoproliferative disorder 9.6
419 neurodevelopmental disorder with spastic diplegia and visual defects 9.6
420 bainbridge-ropers syndrome 9.6
421 alacrima, achalasia, and mental retardation syndrome 9.6
422 melanoma, cutaneous malignant 10 9.6
423 chorea, childhood-onset, with psychomotor retardation 9.6
424 exudative vitreoretinopathy 7 9.6
425 stargardt disease 9.6
426 angiosarcoma 9.6
427 weill-marchesani syndrome 9.6
428 brachydactyly 9.6
429 oculocutaneous albinism 9.6
430 vitelliform macular dystrophy 9.6
431 vitamin b12 deficiency 9.6
432 paraganglioma 9.6
433 arteritic anterior ischemic optic neuropathy 9.6
434 syndromic intellectual disability 9.6
435 adrenal gland pheochromocytoma 9.6
436 autism spectrum disorder 9.6
437 persistent hyperplastic primary vitreous 9.6
438 paroxysmal nocturnal hemoglobinuria 9.6
439 castleman disease 9.6
440 cycloplegia 9.6
441 ametropic amblyopia 9.6
442 microphthalmia 9.6
443 thrombotic thrombocytopenic purpura 9.6
444 hemiplegia 9.6
445 pertussis 9.6
446 solar retinopathy 9.6
447 lens subluxation 9.6
448 spinal meningioma 9.6
449 choroiditis 9.6
450 hypertensive heart disease 9.6
451 diabetic angiopathy 9.6
452 gestational diabetes 9.6
453 lyme disease 9.6
454 iron deficiency anemia 9.6
455 absolute glaucoma 9.6
456 ischemic neuropathy 9.6
457 sympathetic ophthalmia 9.6
458 panuveitis 9.6
459 hemosiderosis 9.6
460 pica disease 9.6
461 vogt-koyanagi-harada disease 9.6
462 hematocele of tunica vaginalis testis 9.6
463 leukemia 9.6
464 pancytopenia 9.6
465 hereditary hemorrhagic telangiectasia 9.6
466 quadriplegia 9.6
467 choreatic disease 9.6
468 hellp syndrome 9.6
469 congenital toxoplasmosis 9.6
470 thrombocytopenia 9.6
471 renovascular hypertension 9.6
472 epilepsy 9.6
473 mononeuritis multiplex 9.6
474 hepatitis c 9.6
475 melanoma 9.6
476 bardet-biedl syndrome 9.6
477 essential thrombocythemia 9.6
478 thrombocytosis 9.6
479 iron metabolism disease 9.6
480 dyskeratosis congenita 9.6
481 idiopathic interstitial pneumonia 9.6
482 interstitial lung disease 9.6
483 purpura 9.6
484 skin disease 9.6
485 pituitary adenoma 9.6
486 syphilis 9.6
487 coronary stenosis 9.6
488 pustulosis of palm and sole 9.6
489 secretory meningioma 9.6
490 lymphoplasmacyte-rich meningioma 9.6
491 familial retinoblastoma 9.6
492 pneumonia 9.6
493 kidney disease 9.6
494 hemoglobinuria 9.6
495 congestive heart failure 9.6
496 malignant choroid melanoma 9.6
497 adenoma 9.6
498 anthrax disease 9.6
499 cocaine abuse 9.6
500 lung disease 9.6
501 collagen disease 9.6
502 vascular dementia 9.6
503 rubella 9.6
504 psoriasis 9.6
505 scotoma 9.6
506 iridocyclitis 9.6
507 postpartum depression 9.6
508 encephalitis 9.6
509 hypoglycemia 9.6
510 albinism 9.6
511 best vitelliform macular dystrophy 9.6
512 sickle cell disease 9.6
513 eisenmenger syndrome 9.6
514 growth hormone deficiency 9.6
515 mitral valve prolapse, familial, x-linked 9.6
516 optic pathway glioma 9.6
517 periodontal ehlers-danlos syndrome 9.6
518 phacomatosis pigmentovascularis 9.6
519 tuberculous uveitis 9.6
520 wyburn-mason syndrome 9.6
521 aneurysm 9.6
522 anoxia 9.6
523 cerebral atrophy 9.6
524 encephalopathy 9.6
525 tremor 9.6
526 angioosteohypertrophic syndrome 9.6
527 cerebrofacial arteriovenous metameric syndrome 9.6
528 rare hereditary hemochromatosis 9.6
529 acute macular neuroretinopathy 9.6
530 argyria 9.6
531 genetic obesity 9.6
532 overgrowth syndrome 9.6
533 precursor t-cell acute lymphoblastic leukemia 9.6

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ALB CCN2 INS KDR LIF MTHFR
2 vision/eye MP:0005391 9.36 AIPL1 AKR1B1 CCN2 INS KDR LIF

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 112, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Travoprost Approved Phase 4 157283-68-6 5282226
7
tannic acid Approved Phase 4 1401-55-4
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
10
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
11
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Ketorolac Tromethamine Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Mitogens Phase 4
19 Endothelial Growth Factors Phase 4
20 Vitamins Phase 4
21 Tocopherols Phase 4
22 Tocotrienols Phase 4
23 Copper Supplement Phase 4
24 retinol Phase 4
25 Antioxidants Phase 4
26 Retinol palmitate Phase 4
27 Vasodilator Agents Phase 4
28 Hormones Phase 4
29 Hemostatics Phase 4
30 Coagulants Phase 4
31 Calcium, Dietary Phase 4
32 Calcium Dobesilate Phase 4
33
Calcium Nutraceutical Phase 4 7440-70-2 271
34
Ranibizumab Approved Phase 3 347396-82-1 459903
35
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
36
Bevacizumab Approved, Investigational Phase 3 216974-75-3
37
Infliximab Approved Phase 3 170277-31-3
38 Anti-Inflammatory Agents Phase 3
39 Hormone Antagonists Phase 3
40 glucocorticoids Phase 3
41 Triamcinolone diacetate Phase 3
42 Triamcinolone hexacetonide Phase 3
43 triamcinolone acetonide Phase 3
44 Immunologic Factors Phase 3
45 Immunosuppressive Agents Phase 3
46 Angiogenesis Inhibitors Phase 3
47 Antineoplastic Agents, Immunological Phase 3
48 Antirheumatic Agents Phase 3
49 Gastrointestinal Agents Phase 3
50 Dermatologic Agents Phase 3
51 Pharmaceutical Solutions Phase 3
52
Regadenoson Approved, Investigational Phase 2 313348-27-5 219024
53
Adenosine Approved, Investigational Phase 2 58-61-7 60961
54
Mecasermin Approved, Investigational Phase 2 68562-41-4
55
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
56 Trace Elements Phase 1, Phase 2
57 Nutrients Phase 1, Phase 2
58 Micronutrients Phase 1, Phase 2
59 Calciferol Phase 1, Phase 2
60
Adalimumab Approved Phase 1 331731-18-1 16219006
61 Ecallantide Approved, Investigational Phase 1 460738-38-9
62
Pimagedine Investigational Phase 1 79-17-4
63 Kallikreins Phase 1
64
Verteporfin Approved, Investigational 129497-78-5
65
Formaldehyde Approved, Vet_approved 50-00-0 712
66
Dipivefrin Approved 52365-63-6 3105
67
Acetylcholine Approved, Investigational 51-84-3 187
68
Phenylephrine Approved 59-42-7 6041
69
Pseudoephedrine Approved 90-82-4 7028
70
Ephedrine Approved 299-42-3 9294
71
Oxymetazoline Approved, Investigational 1491-59-4 4636
72
Sodium citrate Approved, Investigational 68-04-2
73
Nicotine Approved 54-11-5 942 89594
74
Fluocinolone Acetonide Approved, Investigational, Vet_approved 67-73-2 6215
75
Sofosbuvir Approved 1190307-88-0 45375808
76
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
77
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
78
Nitrous oxide Approved, Vet_approved 10024-97-2 948
79
Lutein Approved, Investigational, Nutraceutical 127-40-2 6433159
80
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
81 Photosensitizing Agents
82 Disinfectants
83 Anti-Bacterial Agents
84 Antibiotics, Antitubercular
85 Anesthetics
86 Proxymetacaine
87 Adrenergic alpha-Agonists
88 Adrenergic Agonists
89 Brimonidine Tartrate 70359-46-5
90 Omega 3 Fatty Acid
91 Immunoglobulins
92 Antibodies
93 Respiratory System Agents
94 Cardiotonic Agents
95 Cholinergic Agents
96 Nasal Decongestants
97 Vasoconstrictor Agents
98 Protective Agents
99 Mydriatics
100 Sympathomimetics
101 Citrate
102 Insulin, Globin Zinc
103 insulin
104 Contraceptive Agents
105 Contraceptives, Oral
106 Contraceptives, Oral, Combined
107 Anti-Infective Agents
108 Antiviral Agents
109 Rheumatoid Factor
110 Antineoplastic Agents, Hormonal
111 Antiemetics
112 BB 1101

Interventional clinical trials:

(showing 135, show less)
# Name Status NCT ID Phase Drugs
1 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
2 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
3 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
4 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
5 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
6 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
7 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
8 Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg Suspended NCT03244982 Phase 4 Fluorescein Na 10% Inj 500mg;Fluorescein Na 10% Inj 250mg
9 Bevacizumab and Retinal Vascular Occlusions Unknown status NCT00347711 Phase 3 Intravitreal injection
10 Branch Vein Occlusion Study Completed NCT00000162 Phase 3
11 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
12 Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
13 Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
14 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
15 Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
16 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00105404 Phase 3 Triamcinolone Acetonide
17 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00367133 Phase 3 1mg triamcinolone acetonide;4mg triamcinolone acetonide
18 Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Recruiting NCT03940690 Phase 3 Anti-VEGF injections of bevacizumab
19 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
20 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
21 The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo Unknown status NCT03090087 Phase 2 Regadenoson
22 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
23 Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial. Completed NCT00907153 Phase 1, Phase 2 Placebo
24 Evaluation of the Pain and Visual Outcome Associated With Location of Intravitreal Bevacizumab Injection Completed NCT02790775 Phase 2 Anti-VEGF in quadrant 1;Anti-VEGF in quadrant 2;Anti-VEGF in quadrant 3;Anti-VEGF in quadrant 4
25 Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study Completed NCT01096784 Phase 2 rhIGF-I/rhIGFBP-3
26 Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR). Completed NCT01281098 Phase 2 Intravitreous injection of pegaptanib
27 Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy Completed NCT01280929 Phase 2 Intravitreous injection of ranibizumab
28 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Completed NCT00336323 Phase 2 Bevacizumab;Bevacizumab;Bevacizumab;Bevacizumab
29 A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions. Completed NCT00407355 Phase 1, Phase 2 Intravitreal injection of ranibizumab .3 dose;Intravitreal injection of Ranibizumab .5 dose
30 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab
31 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00369486 Phase 2 40mg triamcinolone;20mg triamcinolone;40mg triamcinolone + laser;20mg triamcinolone + laser
32 Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) Completed NCT00130637 Phase 2 Daclizumab
33 Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00231023 Phase 2 Peribulbar Triamcinolone Acetonide
34 A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY] Recruiting NCT04418427 Phase 2
35 Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion Recruiting NCT03981549 Phase 1, Phase 2
36 Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema Unknown status NCT00468351 Phase 1
37 The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study Unknown status NCT00695682 Phase 1 intravitreal injection of infliximab
38 The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study Unknown status NCT00855608 Phase 1 adalimumab
39 FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease Completed NCT00406796 Phase 1 Ranibizumab
40 Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion Completed NCT01028248 Phase 1 Ranibizumab (Lucentis)
41 Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)
42 An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision Completed NCT02193113 Phase 1 KVD001 Injection
43 Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients Completed NCT02099981 Phase 1 Aminoguanidine
44 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization (MACTEL 2) Completed NCT00685854 Phase 1 Ranibizumab
45 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1) Completed NCT00685503 Phase 1 Ranibizumab
46 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization Completed NCT00457145 Phase 1 Ranibizumab
47 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization Completed NCT00457067 Phase 1 Ranibizumab
48 An Open-Label Phase Ib Study to Evaluate Retinal Imaging After Short-term Use of the Balance Goggles System (BGS) in Patients With Glaucoma Recruiting NCT04035239 Phase 1
49 A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy Enrolling by invitation NCT01736059 Phase 1 CD34+ bone marrow stem cells intravitreal
50 An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Terminated NCT00969293 Phase 1 FOV2302 (Ecallantide)
51 Ocular Imaging Study Using Advanced OCT Unknown status NCT02827071
52 Correlation Between the Visual Acuity and the OCT Pattern of Macular Edema Secondary to Retinal Vein Occlusion Unknown status NCT03489915
53 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel. Unknown status NCT00892619
54 Examination of the Body-fluid Balance in Patients With Retinal Vascular Occlusion Before and During Hemodilution and the Influence of Drinking Habits on the Degree of Body Hydration Unknown status NCT01939119
55 Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion Unknown status NCT01291862
56 Indocyanine Green Angiography-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities. Unknown status NCT01974622 Visudyne
57 Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma Unknown status NCT01209975
58 Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion Unknown status NCT01303276
59 Hypertension Related Damage to the Microcirculation in South Asian: Emergence,Predictive Power and Reversibility Unknown status NCT00331370
60 Phase 1. Validation and Calibration Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348633
61 Retina Microvascularisation and Cardiovascular Heart Disease Prediction Completed NCT01027988
62 CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases Completed NCT03940664
63 Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease Completed NCT04310631 Ranibizumab Injection
64 Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort Completed NCT03864380
65 End-organ Pathology in Childhood Essential Hypertension Completed NCT00005180
66 Identifying Progression of Retinal Disease in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
67 Intravitreal Bevacizumab for Macular Edema Secondary to Major and Macular Branch Retinal Vein Occlusion Completed NCT01219205
68 A 24-Month Cohort Study Assessing the Nature and the Time Course of Structural and Functional Changes to the Retina Following PASCAL Photocoagulation in Proliferative Diabetic Retinopathy Patients Completed NCT02621580
69 Arteriovenous Crossing Sheathotomy Versus Intravitreal Triamcinolone Acetonide Injection for Treatment of Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT00612261
70 Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery: The Role of OCT- Angiography Completed NCT04425954
71 Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning Completed NCT02898480
72 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG) Completed NCT00824824 Dorzolamide 2%-timolol 0.5%;Brimonidine 0.2%-0.5% timolol 0.5
73 Neurovascular Coupling in Eyes of Glaucoma Patients Completed NCT00430209
74 Neurovascular Coupling in Eyes of Glaucoma Patients Completed NCT00429819
75 Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in Newborns Completed NCT02820662
76 Measurement of Retinal Venous Pressure (Retinal Venous Pressure RVP) Under Conditions of Reduced Ambient Pressure and Oxygen Partial Pressure Completed NCT01771757
77 Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects Completed NCT00350129
78 Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans Completed NCT02221089 Escherichia coli Endotoxin
79 Effect of Brimonidine 0.15% on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Tension Glaucoma Completed NCT01105065 brimonidine 0.15%
80 Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation Completed NCT01391247
81 Advanced Glycation End Products as a Biomarker for Accelerated Ageing in Glaucomatous Optic Neuropathy Completed NCT02863224
82 CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity. Completed NCT02346006
83 Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome Completed NCT03459508
84 RETRO CRVO: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion Completed NCT02645747 Aflibercept (Eylea, BAY86-5321)
85 Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers? Completed NCT00431730
86 Retinal Photography in Women With Chest Pain: A WISE/ARIC Collaboration Completed NCT00187954
87 Measurement of the Retinal Venous Pressure (RVP) Under Conditions of Chronically Reduced Ambient Pressure and Oxygen Partial Pressure (Field Study) Completed NCT01771770
88 Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module Completed NCT03279939
89 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Completed NCT02554747
90 Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes Completed NCT01097551 Trinitrin;Neosynephrine 10% collyrium;Iontophoresis with acetylcholine delivery
91 Central Blood Pressure and Pulse Wave Velocity: Relationship to Target Organ Damage and Cardiovascular Morbidity-mortality in Diabetic Patients. An Observational Prospective Study. LOD-DIABETES: Study Protocol Completed NCT01065155
92 Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects Completed NCT01241370
93 Changes of the Subfoveal Hyporeflective Zone After Membrane Peeling With Air Tamponade and Balanced Salt Solution - a Pilot Study Completed NCT02319655
94 The Effect of Eyemasks on Neonatal Stress Following Dilated Retinal Examination, a Randomized Clinical Trial Completed NCT03824782
95 Macular Appearance After Diabetic Vitrectomy for Fibrovascular Proliferation -An Optical Coherence Tomography Study Completed NCT00737022
96 Validation of the Automatic Image Analyzer to Assess Retinal Vessel Caliber (ALTAIR) Completed NCT02087605
97 Comparative Analysis of Three-dimensional Heads-up Display Surgical Platform to Standard Operating Microscope for Vitreoretinal Surgery Completed NCT03075852
98 Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma Completed NCT04242719
99 Cross-sectional Observational Single-center Study to Evaluate Renal Hemodynamics in Patients With Heart Failure and Preserved Ejection Fraction Completed NCT03672591
100 The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study: IMPETUS 2018 - TREAT Completed NCT03113006
101 Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH) Completed NCT02147457
102 Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases Recruiting NCT02141308
103 The UK Facioscapulohumeral Muscular Dystrophy Patient Registry Recruiting NCT04001582
104 Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics Recruiting NCT01994174
105 Contraceptive Pills and Retinal Vascularization (Piluret) Recruiting NCT03964636
106 Impact of Nicotine on Retinal Vascularization (Tabaret) Recruiting NCT03964623
107 Pilot Study: Retinal Vascular Network and Obstructive Sleep Apnea Recruiting NCT03979001
108 Retinal Vessel Analysis (rGA) at the Patient Bed in the Context of Non-traumatic Subarachnoid Haemorrhage Recruiting NCT04094155
109 Study of Retinal Vascular Parameters in Patients With Wilson's Disease Recruiting NCT04408300
110 Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography Recruiting NCT03264391
111 Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects Recruiting NCT01746615
112 Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography Recruiting NCT03233646
113 Navigated Laser In Branch Retinal Vein Occlusion Study Recruiting NCT03651011 Aflibercept Injection [Eylea]
114 Correlation of Microvascular Ophthalmic Disease With Macrovascular Coronary Artery Disease in Trinidad: The EYE-MI TNT Study Recruiting NCT04233619
115 Evaluation of Microvascular Changes in the Perifoveal Vascular Network Using Optical Coherence Tomography Angiography (OCT-A) in Type I Diabetes Mellitus Recruiting NCT03422965
116 Novel Markers for Detecting Early Progression of Glaucoma Recruiting NCT03108443
117 Spectral Domain-Optical Coherence Tomography Angiography of Retinal Diseases Recruiting NCT02510885
118 Optical Coherence Tomography Angiography Analysis of Macular and Papillary Perfusion After Variable Refractive Surgery Methods in Myopic Patients Recruiting NCT04424069
119 Prospective Imaging of the intrAvitreal fluocinoloNe Acetonide Implant Using Fluorescein Angiography and opTical coHerencE tomogRaphy in Uveitis Patients. (PANTHER) Recruiting NCT04340505 Fluocinolone Acetonide
120 Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders (Diabetic Retinopathy, Dry AMD, Hard Drusen Formation) for Alzheimer's Disease Prevention Recruiting NCT03859245
121 Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders Based on Morphological and Hemodynamical Features Recruiting NCT03840265
122 Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2, Using Novel Non-invasive Imaging Methods, in a Longitudinal, Prospective and Interventional Clinical Study With 2 Years of Duration (CORDIS) Active, not recruiting NCT03696810
123 Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection Active, not recruiting NCT04159246 Sofosbuvir (Sovaldi)
124 The Exercise, Arterial Modulation and Nutrition in Youth South Africa (ExAMIN Youth SA) Study Active, not recruiting NCT04056377
125 Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery Not yet recruiting NCT04067856 Bevacizumab Injection
126 A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium Not yet recruiting NCT04008121 Early Phase 1
127 Acute Impact of Cardiac Resynchronization on Vascular Function (RVA-CRT) Not yet recruiting NCT04379401
128 Changes in Retinal Nerve Fiber Layer Thickness Detected by Optical Coherence Tomography in Diabetic Retinopathy After Panretinal Photocoagulation Not yet recruiting NCT03786146
129 Normative Data Collection Study of the Zilia Ocular for the Measurement of Oxygen Saturation in the Retina Not yet recruiting NCT04408677
130 Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging Terminated NCT01834196
131 Multicenter Trial to Investigate the Safety and Efficacy of Vitrectomy With Radial Optic Neurotomy for the Preservation of Visual Function in Subjects With Central Retinal Vein Occlusion (CRVO) Terminated NCT00379223
132 Coupling of Neural Activity and Retinal Blood Flow in Diabetes Terminated NCT01375166
133 Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module Terminated NCT03530449
134 The Effects of Nitrous Oxide on Intraocular Pressure and Ocular Perfusion Terminated NCT00696189
135 A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemodynamics and Intraocular Pressure in Patients With Primary Open-angle Glaucoma Withdrawn NCT00815373 Dorzolamide+Timolol Maleate0.5%;Latanoprost+Timolol Maleate0.5%+Lytears

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

40
Endothelial, Retina, Eye, Bone, Heart, Bone Marrow, Brain

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(showing 4532, show less)
# Title Authors PMID Year
1
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 61 54
20232317 2010
2
The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. 61 54
19639355 2010
3
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 61 54
19916212 2009
4
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 61 54
19646547 2009
5
Risk factors and growth factors in ROP. 54 61
19828269 2009
6
Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. 54 61
19107135 2009
7
Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: potential roles of vascular endothelial growth factor and nitric oxide. 61 54
19374851 2009
8
Feedback mechanism between blood vessels and astrocytes in retinal vascular development. 61 54
19577710 2009
9
Association of vitreous inflammatory factors with diabetic macular edema. 61 54
19118698 2009
10
VEGF-induced choroidal damage in a murine model of retinal neovascularisation. 54 61
18523088 2008
11
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. 54 61
18483622 2008
12
Aquaporin 1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells. 61 54
18275976 2008
13
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. 61 54
16943230 2007
14
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. 61 54
17420693 2007
15
Molecular targets for retinal vascular diseases. 61 54
17133346 2007
16
Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. 61 54
17341153 2007
17
Retinopathy of prematurity. 61 54
17332988 2007
18
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. 54 61
17293777 2007
19
Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. 54 61
16643897 2006
20
Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. 54 61
16723489 2006
21
Therapeutic potential of angiostatin in diabetic nephropathy. 54 61
16394111 2006
22
Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. 54 61
16123442 2005
23
Predominant rod photoreceptor degeneration in Leber congenital amaurosis. 54 61
16052170 2005
24
Angiopoietin concentrations in diabetic retinopathy. 61 54
15774928 2005
25
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. 61 54
15258030 2004
26
VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. 54 61
15303088 2004
27
Pathogenesis of retinopathy of prematurity. 54 61
15135797 2004
28
VEGF and KDR gene expression during human embryonic and fetal eye development. 61 54
14691147 2004
29
An unusual retinal vascular morphology in connection with a novel AIPL1 mutation in Leber's congenital amaurosis. 61 54
12881340 2003
30
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. 54 61
12652648 2003
31
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene. 61 54
12644949 2003
32
Pigment epithelium-derived factor expression in the developing mouse eye. 61 54
12447163 2002
33
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. 61 54
11596663 2001
34
Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. 54 61
11340407 2001
35
Role of vascular endothelial growth factor in diabetic vascular complications. 54 61
10997700 2000
36
[Cell biology of intraocular vascular diseases]. 54 61
10643294 1999
37
VEGF increases retinal vascular ICAM-1 expression in vivo. 61 54
10393052 1999
38
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. 54 61
10211121 1998
39
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. 61 54
9287049 1997
40
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 54 61
9227268 1997
41
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 61 54
9046048 1997
42
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. 61 54
9008628 1997
43
Vascular endothelial growth factor--its role in retinal vascular proliferation. 54 61
7526213 1994
44
Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. 61 54
8139268 1994
45
Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. 61 54
8226103 1993
46
Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. 54 61
2091899 1990
47
Optical coherence tomography angiography findings in macular toxoplasma retinochoroiditis: A case report. 61
32551402 2020
48
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia. 61
32114640 2020
49
Structure-function correlation of localized visual field defects and macular microvascular damage in primary open-angle glaucoma. 61
32240673 2020
50
Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy. 61
32051147 2020
51
circRNA_0084043 contributes to the progression of diabetic retinopathy via sponging miR-140-3p and inducing TGFA gene expression in retinal pigment epithelial cells. 61
32259630 2020
52
Pericyte Bridges in Homeostasis and Hyperglycemia. 61
32321760 2020
53
Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. 61
32575487 2020
54
Ultra-widefield fundus fluorescein angiography findings in patients with ankylosing spondylitis experiencing uveitis. 61
32488588 2020
55
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. 61
32556494 2020
56
A novel interaction between soluble epoxide hydrolase and the AT1 receptor in retinal microvascular damage. 61
32360774 2020
57
Retinal Vascular Reactivity in Type 1 Diabetes Patients Without Retinopathy Using Optical Coherence Tomography Angiography. 61
32574352 2020
58
Circular RNA-ZNF532 regulates diabetes-induced retinal pericyte degeneration and vascular dysfunction. 61
32343678 2020
59
Automated diagnoses of age-related macular degeneration and polypoidal choroidal vasculopathy using bi-modal deep convolutional neural networks. 61
32499330 2020
60
Aucuba japonica extract inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy, with its bioactive components preventing VEGF-induced retinal vascular hyperpermeability. 61
32566207 2020
61
Inhibition of acetylcholinesterase attenuated retinal inflammation via suppressing NF-κB activation. 61
32184102 2020
62
Measuring intraocular antibodies in eyes treated with anti-vascular endothelial growth factor. 61
32253011 2020
63
A novel method for electroretinogram assessment in patients with central retinal vein occlusion. 61
31912261 2020
64
Comparison of foveal avascular zone and retinal vascular density in healthy Chinese and Caucasian adults. 61
31773884 2020
65
Primate model of chronic retinal neovascularization and vascular leakage. 61
32275921 2020
66
Involvement of Gi protein-dependent BKCa channel activation in β2-adrenoceptor-mediated dilation of retinal arterioles in rats. 61
32500188 2020
67
Spectrum of peripheral retinal ischemia in Wyburn-Mason syndrome. 61
32181415 2020
68
Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures. 61
31094280 2020
69
SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. 61
31356494 2020
70
All-trans-Retinaldehyde Contributes to Retinal Vascular Permeability in Ischemia Reperfusion. 61
32492112 2020
71
Single-cell profiling reveals an endothelium-mediated immunomodulatory pathway in the eye choroid. 61
32196081 2020
72
Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. 61
32527301 2020
73
Optical coherence tomography angiography findings in axial spondylarthritis. 61
32219479 2020
74
Systemic hypertension associated retinal microvascular changes can be detected with optical coherence tomography angiography. 61
32533105 2020
75
OxLDL enhances choroidal neovascularization lesion through inducing vascular endothelium to mesenchymal transition process and angiogenic factor expression. 61
32087305 2020
76
Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study. 61
32503932 2020
77
Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. 61
32327351 2020
78
Investigating the Role of PPARβ/δ in Retinal Vascular Remodeling Using Pparβ/δ-Deficient Mice. 61
32575793 2020
79
Multiple retinal vascular occlusions in Leriche syndrome. 61
32461464 2020
80
Non-invasive evaluation of retinal vascular remodeling and hypertrophy in humans: intricate effect of ageing, blood pressure and glycaemia. 61
32494923 2020
81
Do body mass index and waist-to-height ratio over the preceding decade predict retinal microvasculature in 11-12 year olds and midlife adults? 61
32424266 2020
82
Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. 61
32043162 2020
83
Refractory adult Coats disease treated with dexamethasone intravitreal implant: A case report. 61
32443362 2020
84
Stabilization of myeloid-derived HIFs promotes vascular regeneration in retinal ischemia. 61
31583505 2020
85
[Indications for fluorescein angiography and optical coherence tomography angiography (OCTA) in medical retina: Changes from 2015 and 2018]. 61
32115267 2020
86
Microglia Contribution to the Regulation of the Retinal and Choroidal Vasculature in Age-Related Macular Degeneration. 61
32423062 2020
87
Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration. 61
31654481 2020
88
Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients. 61
31965393 2020
89
The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization. 61
31883121 2020
90
Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization. 61
32444495 2020
91
CircRNA cPWWP2A: an emerging player in diabetes mellitus. 61
32415512 2020
92
Dysregulation of miR-210 is involved in the development of diabetic retinopathy and serves a regulatory role in retinal vascular endothelial cell proliferation. 61
32498701 2020
93
[Vitreous body hemorrhage-How long can one wait?] 61
32385553 2020
94
Extended Zone Retinal Vascular Caliber and Risk of Diabetic Retinopathy in Adolescents with Type 1 Diabetes. 61
32446907 2020
95
The future of retinal imaging. 61
32168003 2020
96
Retinal capillary oximetry with visible light optical coherence tomography. 61
32398376 2020
97
Visual Function and Disability Are Associated with Increased Retinal Volumetric Vessel Density in Patients with Multiple Sclerosis. 61
31926161 2020
98
Optical coherence tomography angiography findings in young β-thalassemia patients. 61
31902243 2020
99
A mouse model for kinesin family member 11 (Kif11)-associated familial exudative vitreoretinopathy. 61
31993640 2020
100
Associations between cannabis use and retinal vessel diameter in young adults. 61
30837202 2020
101
Heart rate variability, the dynamic nature of the retinal microvasculature and cardiac stress: providing insight into the brain-retina-heart link: the SABPA study. 61
31278382 2020
102
Cardiovascular health and retinal microvascular geometry in Australian 11-12 year-olds. 61
31836514 2020
103
Retinal Vascular Changes in Radiation Maculopathy after Intravitreal Ranibizumab by Optical Coherence Tomography Angiography. 61
32471149 2020
104
Optical coherence tomography angiography reveals vascular alterations in pediatric commotio retinae. 61
32403943 2020
105
A CTGF-YAP Regulatory Pathway Is Essential for Angiogenesis and Barriergenesis in the Retina. 61
32502964 2020
106
Association Between Caliber of Retinal Vessels and Cardiovascular Disease: a Systematic Review